LICENSES ACQUIRED (Details) - USD ($) $ / shares in Units, $ in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
Nov. 16, 2021 |
Jun. 29, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Licenses acquired | ||||
| Second installment payable | $ 8,137 | $ 12,659 | ||
| D F D Agreement | ||||
| Licenses acquired | ||||
| Amount payable | $ 10,000 | 10,000 | ||
| First installment paid | 2,000 | |||
| Second installment payable | $ 8,000 | |||
| Period within which second installment is payable | 90 days | |||
| Amount payable to fund clinical trials | $ 24,000 | |||
| D F D Agreement | Contingent Payment Derivative | ||||
| Licenses acquired | ||||
| Unregistered shares issued | 545,131 | |||
| Volume weighted average price per share related to shares issued | $ 9.1721 | |||
| Number of days for calculating weighted average price | 15 days | 15 days | ||
| D F D Agreement | Minimum | ||||
| Licenses acquired | ||||
| Percentage of royalties payable on net sales | 10.00% | |||
| D F D Agreement | Maximum | ||||
| Licenses acquired | ||||
| Threshold additional contingent regulatory and commercial milestone payments payable | $ 163,000 | |||
| Percentage of royalties payable on net sales | 15.00% |
| X | ||||||||||
- Definition Amount payable to fund the clinical trials under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The percentage of royalties payable on net sales under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The number of trading days for calculating volume weighted average price. No definition available.
|
| X | ||||||||||
- Definition The period within which the second installment becomes payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Second installment payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Threshold additional contingent regulatory and commercial milestone payments payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Total amount payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Total number of unregistered common shares of an entity that have been sold or granted to shareholders. No definition available.
|
| X | ||||||||||
- Definition Volume weighted average price per share related to shares issued. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|